Fish oil and protein combo tested for COPD muscle loss
NCT ID NCT01624792
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether taking fish oil supplements (containing EPA and DHA) along with a protein drink could help people with COPD build muscle. Sixty-four participants took either fish oil or a placebo for four weeks. Researchers measured muscle protein synthesis to see if the combination improved muscle building.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Fish oil (eicosapentaenoic acid and docosahexaenoic acid) and protein (casein)
- What this could lead to
- If successful, this could point toward a nutritional strategy to help COPD patients maintain or gain muscle mass.
- What could go wrong
- This is a small, early-stage study with only 64 participants. The results may not apply to all COPD patients, and the effect on muscle mass may be minimal.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
64 people
The number who actually took part.
- Started
-
Oct 2011
- Finished
-
Jun 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Inclusion criteria COPD subjects: * Ability to walk, sit down and stand up independently * Age 45 years or older * Ability to lay in supine or elevated position for 8 hours * Diagnosis of moderate to severe chronic airflow limitation, defined as measured forced expiratory volume in one second (FEV1) ≤ 70% of referen¬ce FEV1 * Clinically stable condition and not suffering from respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 \> 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the study * Shortness of breath on exertion * Willingness and ability to comply with the protocol, including: * Refraining from alcohol consumption (24 h) and intense physical activities (72h) prior to each study visit * Adhering to fasting state from 10 pm ± 2h onwards the day prior to each study visit Inclusion criteria healthy control subjects: * Healthy male or female according to the investigator's or appointed staff's judgment * Ability to walk, sit down and stand up independently * Age 45 years or older * Ability to lay in supine or elevated position for 8 hours * No diagnosis of COPD and forced expiratory volume in one second (FEV1) \> 80% of referen¬ce FEV1 * Willingness and ability to comply with the protocol, including: * Refraining from alcohol consumption (24 h) and intense physical activities (72h) prior to each study visit * Adhering to fasting state from 10 pm ± 2h onwards the day prior to each study visit Exclusion Criteria: * Any condition that may interfere with the definition 'healthy subject' according to the investigator's judgment (for healthy control group only) * Established diagnosis of malignancy * Established diagnosis of Diabetes Mellitus * History of untreated metabolic diseases including hepatic or renal disorder * Presence of acute illness or metabolically unstable chronic illness * Recent myocardial infarction (less than 1 year) * Any other condition according to the PI or study physicians would interfere with proper conduct of the study / safety of the patient * BMI ≥ 40 kg/m2 * Dietary or lifestyle characteristics: * Use of supplements containing EPA+DHA 3 months prior to the first test day Use of protein or amino acid containing nutritional supplements within 5 days of first study day * Current alcohol or drug abuse * Indications related to interaction with study products: * Known allergy to milk or milk products * Known hypersensitivity to fish and/or shellfish, Swanson EFAs Super EPA Fish oil or any of its ingredients, Swanson EFAs Certified Organic Extra Virgin Olive oil or any of its ingredients * Contraindications to biopsy procedure: * Platelet count (PLT) \< 100,000 * History of hypo- or hyper-coagulation disorders including use of a Coumadin derivative, history of deep venous thrombosis (DVT), or pulmonary embolism (PE) at any point in lifetime * Currently taking anti-thrombotics and cannot stop for 7 days (i.e. medical indication) * Allergy to local anesthetic * Use of long-term oral corticosteroids or short course of oral corticosteroids in the preceding month before enrollment * Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas A&M University
College Station, Texas, 77843, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a COPD flare stun the heart? study watches for hidden strain
- Can better training get doctors to talk about what matters most to dying veterans?
- Can an injected antibody calm inflamed lungs and cut COPD flare-ups?
- Detailed lung scans could map COPD damage more precisely
- Can AI help nurses guide At-Risk seniors to better care and lower costs?
- Fine-Mist inhalers aim to reach deep lungs in COPD